Get started
Author

Y. Gloria Meng

Observed names: Yingying Meng, Yu-Qing Meng
ORCID: 0000-0001-6483-2891
Observed ORCIDs: 0000-0001-6483-2891, 0009-0001-7230-6936
OpenAlex ID: A5086464111
Synthesis and anti-liver fibrosis activity of imidazole and thiazole compounds containing amino acids
2024 · Yu-Qing Meng, Jie Ren, et al. · European Journal of Medicinal Chemistry · 18
Investigation of the genome-wide signatures underlying the micropapillary carcinoma components in colorectal cancers
2024 · Yingying Meng, Zhao Zhang, et al. · Genes & Diseases
Supplementary Table 1, Figures 1 - 3 from Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
2023 · Priti S. Hegde, Adrian M. Jubb, et al.
PDF
Data from Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
2023 · Priti S. Hegde, Adrian M. Jubb, et al.
Data from Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
2023 · Priti S. Hegde, Adrian M. Jubb, et al.
Supplementary Figure 1 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
Supplementary Figure Legends 1-6 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
Supplementary Figure 3 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
Supplementary Figure 6 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
Supplementary Tables 1 - 4 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
PDF
Supplementary Figure 4 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
PDF
Supplementary Figure 5 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
PDF
Supplementary Figure 2 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
PDF
Supplementary Figure 1 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
PDF
Supplementary Figure 4 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
Supplementary Tables 1 - 4 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
Supplementary Figure 5 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
Supplementary Figure 2 from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
Data from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
Data from A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
2023 · Yik Andy Yeung, Xiumin Wu, et al.
Works count: 20
Citation count: 18
H-index: 1
I10-index: 1
Year
Topic
Type